Biology is not modular. A mutation in a gene does not act in isolation — it alters transcription, reshapes the proteome, and redirects metabolic flux. Understanding a disease, designing a therapeutic, or validating a biomarker requires seeing across all of these layers simultaneously. Yet most sequencing studies still capture only one data type: either the genome, or the transcriptome, or the proteome.
Multi-omics integration is the practice of combining data from two or more molecular measurement platforms — genomics, transcriptomics, proteomics, and metabolomics — to build a more complete picture of biological state.[1] It is not a trend. It is what the biology actually demands.
What Each Omics Layer Contributes
Each data type answers a different question about the same underlying biological system. Genomics reveals the heritable and somatic mutations present in DNA. Transcriptomics captures which genes are being expressed, at what level, and in which cell types. Proteomics shows which proteins are actually produced and post-translationally modified. Metabolomics reads the downstream biochemical state of the cell — the substrates, intermediates, and products that reflect metabolic flux most closely to the clinical phenotype.
Figure 1. Molecular information flows from DNA through RNA and protein to the metabolic phenotype. All four layers converge in the integrated insight hub where tools like MOFA+, DIABLO, and mixOmics identify shared biological patterns.
| Omics Layer | Measurement | Key Insight | Common Platform |
|---|---|---|---|
| Genomics | DNA sequence variants | Heritable & somatic mutations | WGS, WES, SNP array |
| Transcriptomics | RNA abundance | Gene expression, splicing, fusion | Bulk RNA-seq, scRNA-seq |
| Proteomics | Protein identity & quantity | Functional output, PTMs | LC-MS/MS, TMT |
| Metabolomics | Small molecule levels | Metabolic flux, phenotype | NMR, GC-MS, LC-MS |
Table 1. Each omics modality contributes distinct information; integration reveals the biological mechanism.
Why Single-Modality Analysis Falls Short
The limitations of single-omics analysis are well documented and practically significant.
- Genomic mutations do not guarantee functional impact. Many mutations are passengers, not drivers. Only transcriptomic or proteomic evidence of dysregulated downstream pathways can confirm functional consequence.
- Transcriptomic signatures can be misleading. A gene upregulated at the RNA level may not produce more protein due to translational repression or post-translational degradation.
- Proteomic changes may not be traceable to transcription. They may arise from protein stability changes, altered degradation rates, or metabolic co-factor availability.
- Metabolic reprogramming is often the closest readout to therapeutic response — but metabolomics without genomic or transcriptomic context cannot identify the upstream molecular cause.
Practical Integration Strategies
Multi-omics integration can be implemented at several levels of sophistication depending on study design, sample size, and analytical objectives.[1]
Figure 2. The three integration strategies differ in where data layers are merged. Early integration combines raw data immediately into a joint model. Late integration analyses each layer independently before combining scores. Intermediate integration — the clinical gold standard — applies tools like MOFA+ and DIABLO to identify shared latent factors across layers.
Early integration combines raw or lightly processed data from multiple modalities before analysis. This approach maximises information capture but requires careful handling of batch effects and missing data across platforms.
Late integration analyses each omics layer independently, then combines results at the level of pathways, signatures, or statistical scores.[2] This is more tractable for smaller datasets and allows methodological flexibility in the per-layer analysis.
Intermediate integration — the current gold standard for most clinical applications — uses dimensionality reduction methods such as MOFA+[3] or multi-block PLS-DA (DIABLO)[2] to identify shared latent factors across omics layers, revealing coordinated variation that drives biological outcomes. Work in breast cancer proteogenomics has demonstrated how this approach connects somatic mutations to downstream signalling in ways that single-layer analysis misses.[4]
| Integration Approach | Data Types Combined | Key Tool / Framework |
|---|---|---|
| Correlation-based | Any pairwise omics layers | WGCNA, mixOmics |
| Multi-block PLS | Genomics + transcriptomics + metabolomics | DIABLO (mixOmics) |
| Factor analysis | Any combination | MOFA+ (Multi-Omics Factor Analysis) |
| Network integration | Transcriptomics + proteomics | STRING / Cytoscape / iGraph |
| Dimensionality reduction | High-dim multi-omics | UMAP, CITE-seq (Seurat WNN) |
| Machine learning ensemble | All layers for prediction | sklearn / TensorFlow with omics features |
Table 2. Computational approaches for integrating multiple omics data layers.[6]
The Zetobit Approach
At Zetobit, we design multi-omics studies from the ground up — ensuring that sample collection, processing, and data generation protocols are harmonised across modalities before a single sample is sequenced. Retrospective integration of data collected under different protocols is technically possible but introduces batch effects that can obscure true biological signal. Getting the design right from the start is the most important investment in a multi-omics programme.
References
- Subramanian I, et al. Multi-omics data integration, interpretation, and its application. Bioinformatics and Biology Insights. 2020;14:1177932219899051. doi:10.1177/1177932219899051 ↗
- Rohart F, et al. mixOmics: an R package for omics feature selection and multiple data integration. PLOS Computational Biology. 2017;13:e1005752. doi:10.1371/journal.pcbi.1005752 ↗
- Argelaguet R, et al. MOFA+: a statistical framework for comprehensive integration of multi-modal single-cell data. Genome Biology. 2020;21:111. doi:10.1186/s13059-020-02015-1 ↗
- Mertins P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55–62. doi:10.1038/nature18003 ↗
- The Cancer Genome Atlas Network. Comprehensive molecular characterisation of human colon and rectal cancer. Nature. 2012;487:330–337. doi:10.1038/nature11252 ↗
- Huang S, et al. More is better: recent progress in multi-omics data integration methods. Frontiers in Genetics. 2017;8:84. doi:10.3389/fgene.2017.00084 ↗
Designing a multi-omics study or integrating existing datasets across platforms? Zetobit builds analysis pipelines that are scientifically rigorous and publication-ready.
Book a Discovery Call